Cd70 antibody drug conjugates and methods of using the same

A conjugate comprising:

• a Binding unit bound to one or more Drug units by one or more Linkers, wherein:
• (1) the Binding unit comprises a heavy chain variable (VH) region and a light chain variable (VL) region, the VH region comprising complementarity determining regions HCDR1, HCDR2 and HCDR3 disposed in heavy chain variable region framework regions and the VL region comprising LCDR1, LCDR2 and LCDR3 disposed in light chain variable region framework regions, the VH and VL CDRs having amino acids sequences selected from the sets of amino acid sequences set forth in the group consisting of:
• a. SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:13, SEQ ID NO:24, SEQ ID NO:25 and SEQ ID NO:26, respectively;
• b. SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:14, SEQ ID NO:24, SEQ ID NO:25 and SEQ ID NO:26, respectively;
• c. SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:15, SEQ ID NO:24, SEQ ID NO:25 and SEQ ID NO:26, respectively;
• d. SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25 and SEQ ID NO:18, respectively;
• and
• e. SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25 and SEQ ID NO:26;
• respectively;
• (2) each Linker has the following formula (I):
• or a salt thereof, wherein:
• L1 is a Stretcher unit covalently bound to the Binding unit, wherein the wavy (˜) line indicates an attachment site for the Binding unit;
• AA is an Amino Acid unit having from 1 to 12 subunits;
• s is 0 or 1;
• L2 is a Linker Subunit having from 1 to 4 attachment sites for a Drug unit, wherein the double wavy (≈) line indicates an attachment site for the Drug Unit;
• and
• wherein at least one Polar unit is present within the Amino Acid unit, the Linker Subunit, the Stretcher unit, or combinations thereof, and wherein the Polar unit(s) is selected from Sugar units, PEG units, Carboxyl units, and combinations thereof;
• and
• (3) each Drug unit is covalently attached to each Linker Subunit at (≈).